Morphiex Biotherapeutics | Morphiex’s CD47 Inhibitor in Combination with Ipilimumab Enhances Survival in Melanoma
512
post-template-default,single,single-post,postid-512,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-content-sidebar-responsive,qode-theme-ver-13.8,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom

Morphiex’s CD47 Inhibitor in Combination with Ipilimumab Enhances Survival in Melanoma

Check out our new publication in the Journal of Immunology & Immunotherapy demonstrating the synergy of Morphiex’s CD47 inhibitor (MBT-001) with ipilimumab (CTLA4) and CAR-T.

https://link.springer.com/article/10.1007/s00262-019-02397-7

MBT-001 was developed at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). MBT-001 is exclusively licensed to Morphiex for the treatment of cancer as a monotherapy or in combination with other modalities such as chemotherapy, immune checkpoint inhibitors, CAR-T and many others. In addition, Morphiex has entered into a cooperative research and development agreement (CRADA) with the NIH/NCI to accelerate the development of MBT-001.



Location

240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com

Social Media

Twitter Facebook LinkedIn